IP Group — Exit target of over £250m by end-FY27 reiterated
18/09/2025
IP Group continues to deliver a meaningful level of realisations with £30.3m in proceeds generated in H125, more than two-thirds of which came from four life sciences companies (Intelligent Ultrasound, Centessa, Abliva and Hinge Health). Importantly, management reiterated its target of delivering over £250m in realisation proceeds between FY25 and FY27, which excludes any potential exit proceeds from Oxford Nanopore (ONT) and represents roughly 50% of IP Group’s current market capitalisation. IP Group’s NAV was supported by the rising share price of ONT, and the successful IPO and subsequent performance of Hinge Health (for which IP Group’s lock-up expires in November 2025). This was offset by a net decline in the carrying values of private holdings, most notably Oxa Autonomy and Artios Pharma due to funding delays, and £14.2m of fx headwinds. This led to a slight 1.5% fall in NAV in H125 to 96.2p, which was more than reversed post reporting date by the continued strength of listed holdings, bringing IP Group’s NAV to c 100p as of 12 September 2025.
IP Group – capital markets day
06/08/2025
IP Group hosted a capital markets day on 26 June 2025, which included presentations on the group’s investment strategy, pipeline, major themes and portfolio companies.
IP Group – executive interview
07/05/2025
In this interview, IP Group’s CEO, Greg Smith, discusses the company’s performance and outlook. He explores the factors behind its fivefold year-on-year increase in realisations to £180m in FY24 and what underpins the company’s target of delivering a further £250m in exits between now and FYE27. Greg also discusses the robust pipeline of opportunities, particularly in life sciences and deeptech, with several companies advancing through clinical trials and preparing for potential exits. He also gives an update on the company’s priorities for allocation between supporting existing portfolio companies, making new investments and returning value to shareholders through buybacks. Lastly, he touches on the broader venture capital landscape, including the impact of the Mansion House Compact and the evolving sentiment towards VC investments. IP Group helps to create, build and support IP-based companies internationally. It focuses on companies that meaningfully contribute to regenerative (renewable), healthier (life sciences) and tech-enriched (deep tech) futures.